London, UK — (PRESS RELEASE JET) — 10/19/2017 — The market for drugs to treat skin conditions is growing at nearly 7% year on year in the Middle East and South America, significantly outpacing the global average of around 5%. The rapid growth in these markets makes them present significant opportunities to manufacturers of drugs used to treat dermatological problems. In contrast, growth in the world’s largest dermatology drugs market, North America, is only 4% a year and that in Western Europe, also a large market, is a mere 3%.
Dermatology drugs are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.
The relatively rapid growth of sales for these drugs in the Middle East and South America is partly explained by the concnetration of their populations in subtropical regions where dermatological disease incidence is high. Another factor is the sale of many of these drugs without prescription so that limited access to medical services does not hold back the market, especially as the populations urbanise. Regional growth of GDP per capita is also a factor in high market growth.
Despite their rapid growth, however, the two growth-leading regions will continue among the smaller skin disease markets – in 2020 the Middle East will account for only 4% of global sales and even South America, with its much larger population, for only about 10%.
The global market for dermatology drugs itself is a comparatively small one, representing 3.5% of the global market for pharma as a whole.
The leading competitor in the global market for dermatology drugs is the USA’s Johnson & Johnson, closely followed by Allergan, which is headquarted in Dublin, Eire, and Galderma, with its headquarters in Lausanne, Switzerland. These three companies share about a third of the market between them. Nearly 50% is split among a large number of small pharma businesses.
One of the trends which is shaping the market is a use of genome testing to speed clinical trials of drugs. Drug manufacturing companies are using genome testing to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs.
Where to Learn More
Read Dermatology Drugs Market Global Report 2017 from The Business Research Company for information on the following:
Markets Covered: Antibacterial, Anti-Fungal, Anti-Viral
Companies Mentioned: Galderma (Nestle Skin Health), Johnson & Johnson, AbbVie, GlaxosmithKline, and Pfizer
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Interested to know more? Here is a full scope of Biologics and Pharmaceutical Drugs Market reports to explore:
1. Pharmaceutical Drugs Market Global Report 2017
2. Anti-infective Drugs Market Global Report 2017
3. Cardiovascular Drugs Market Global Report 2017
4. Central Nervous System Drugs Market Global Report 2017
5. Genito-urinary Drugs Market Global Report 2017
6. Hematology Drugs Market Global Report 2017
7. Metabolic Disorder Drugs Market Global Report 2017
8. Musculoskeletal Disorders Drugs Market Global Report 2017
9. Ophthalmology Drugs Market Global Report 2017
10. Gastrointestinal Drugs Market Global Report 2017
11. Respiratory Drugs Market Global Report 2017
12. Biologics Market Global Report 2017
13. Oncology Drugs Market Global Report 2017
About The Business Research Company
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company’s management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations. The Business Research Company’s Consultant have master’s qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company’s Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.
Powered by WPeMatico